208 related articles for article (PubMed ID: 24960297)
1. Two cholesterol derivative-based PEGylated liposomes as drug delivery system, study on pharmacokinetics and drug delivery to retina.
Geng S; Yang B; Wang G; Qin G; Wada S; Wang JY
Nanotechnology; 2014 Jul; 25(27):275103. PubMed ID: 24960297
[TBL] [Abstract][Full Text] [Related]
2. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
3. Impact of interfacial cholesterol-anchored polyethylene glycol on sterol-rich non-phospholipid liposomes.
Cui ZK; Edwards K; Nieto Orellana A; Bastiat G; Benoit JP; Lafleur M
J Colloid Interface Sci; 2014 Aug; 428():111-20. PubMed ID: 24910042
[TBL] [Abstract][Full Text] [Related]
4. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
[TBL] [Abstract][Full Text] [Related]
5. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU).
Park SM; Kim MS; Park SJ; Park ES; Choi KS; Kim YS; Kim HR
J Control Release; 2013 Sep; 170(3):373-9. PubMed ID: 23770213
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization.
Nie Y; Ji L; Ding H; Xie L; Li L; He B; Wu Y; Gu Z
Theranostics; 2012; 2(11):1092-103. PubMed ID: 23227125
[TBL] [Abstract][Full Text] [Related]
7. Physical stability of cholesterol derivatives combined with liposomes and their in vitro behavior.
Yang B; Geng SY; Wang JY
Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():4114-7. PubMed ID: 24110637
[TBL] [Abstract][Full Text] [Related]
8. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
9. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
[TBL] [Abstract][Full Text] [Related]
10. Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy.
Pasut G; Paolino D; Celia C; Mero A; Joseph AS; Wolfram J; Cosco D; Schiavon O; Shen H; Fresta M
J Control Release; 2015 Feb; 199():106-13. PubMed ID: 25499917
[TBL] [Abstract][Full Text] [Related]
11. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
12. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
13. Enhanced retention and anti-tumor efficacy of liposomes by changing their cellular uptake and pharmacokinetics behavior.
Li Y; Liu R; Yang J; Shi Y; Ma G; Zhang Z; Zhang X
Biomaterials; 2015 Feb; 41():1-14. PubMed ID: 25522960
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
Jiang W; Lionberger R; Yu LX
Bioanalysis; 2011 Feb; 3(3):333-44. PubMed ID: 21320053
[TBL] [Abstract][Full Text] [Related]
15. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers.
Boakye CH; Patel K; Singh M
Int J Pharm; 2015 Jul; 489(1-2):106-16. PubMed ID: 25910414
[TBL] [Abstract][Full Text] [Related]
17. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
18. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies.
Li C; Cui J; Wang C; Zhang L; Xiu X; Li Y; Wei N; Li Y; Zhang L
J Pharm Pharmacol; 2011 Mar; 63(3):376-84. PubMed ID: 21749385
[TBL] [Abstract][Full Text] [Related]
19. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
20. Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition.
Kopecka J; Salzano G; Campia I; Lusa S; Ghigo D; De Rosa G; Riganti C
Nanomedicine; 2014 Jan; 10(1):77-87. PubMed ID: 23850894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
